

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 July 2023 (20.07.2023)



(10) International Publication Number
WO 2023/137395 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01) *C12N 5/10* (2006.01)
A61P 9/00 (2006.01) *C12N 15/85* (2006.01)

(21) International Application Number:

PCT/US2023/060582

(22) International Filing Date:

12 January 2023 (12.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/299,177 13 January 2022 (13.01.2022) US
63/310,359 15 February 2022 (15.02.2022) US
63/335,805 28 April 2022 (28.04.2022) US

(71) Applicant: **INGENIA THERAPEUTICS INC.** [US/US];
Innovation Center Biolabs, 2nd Fl., 650 East Kendall St.,
Cambridge, Massachusetts 02142 (US).

(72) Inventors: **CHOO, Minkyung**; Innovation Center Biolabs,
2nd Fl., 650 East Kendall St., Cambridge, Massachusetts
02142 (US). **KIM, Kwangsoo**; Innovation Center Biolabs,
2nd Fl., 650 East Kendall St., Cambridge, Massachusetts
02142 (US). **HAN, Sangyeul**; Innovation Center Biolabs,
2nd Fl., 650 East Kendall St., Cambridge, Massachusetts
02142 (US). **DUROST, Philip**; Innovation Center Biolabs,

2nd Fl., 650 East Kendall St., Cambridge, Massachusetts
02142 (US).

(74) Agent: **SCHOENHARD, Amy E.L.** et al.; McNeill Baur
PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge,
Massachusetts 02140 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: VEGF AND TIE2-BINDING FUSION PROTEIN AND USES THEREOF




Fig. 13

(57) Abstract: The present disclosure refers to a fusion protein having an antibody against Tie-2 or antigen-binding fragment thereof and a vascular endothelial growth factor (VEGF)-binding domain, methods for making the fusion protein, and pharmaceutical compositions and methods for preventing or treating angiogenic diseases or regulating angiogenesis, endothelial signaling, inflammation, and/or vascular leakage, which comprise the fusion protein.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))